NEWS: Curebase closes $40M Series B with strategic investment by Gilead. Read about it in TechCrunch, Fierce Biotech, andEndpoints News.

Press release

Curebase Secures $40M Series B

SAN FRANCISCO, May 5, 2022 — Curebase, a company committed to democratizing access to clinical studies, has raised $40 million in Series B funding to continue development of its end-to-end clinical trial execution model, virtual and hybrid site capabilities, and full eClinical software platform to run modern, patient-centric clinical trials. Since 2018,Curebase has established itself as a leader in decentralized clinical trials(DCTs) and patient-centric clinical trial software. This funding will deepen Curebase’s breadth of capabilities beyond the virtual experience: via more complex site and community healthcare interfaces, a richer range of clinical software and services, and more robust capabilities for interventional drug sponsors and global studies.

Industry Ventures led this funding round, which included new institutional investors Acrew Capital, World Innovation Lab and Positive Sum, and existing investors GGV Capital, who led the Series A, Bold Capital and Xfund. The round also included a strategic investment by global biopharmaceutical company Gilead Sciences to deepen their partnership with Curebase on implementing DCT and hybrid capabilities in interventional trials.

In addition, Gaingels, an investment syndicate that focuses on startups dedicated to building diverse and inclusive teams participated in the round. Since its founding in 2017, Curebase has raised a total of $59 million.

“We look to invest in technology companies that we believe are transforming massive, inefficient industries,” said Fanni Fan, vice president at Industry Ventures. “Curebase stood out to us for its full-vertical approach, comprehensive patient-centric software platform, and outstanding response from customers. We believe this investment will allow them to scale their model in a market that is rapidly growing on a global level, and continue expanding into the most complex drug study designs.”

Clinical research has traditionally suffered from difficult enrollment, retention, and diversity. Curebase’s model enables the inclusion of underrepresented patient populations otherwise excluded from clinical trials and expands access overall to studies to solve this challenge.  The company's virtual and hybrid research sites offer patients a unique opportunity to participate in clinical studies, regardless of their location via community provider facilities and home-based care. The Curebase platform empowers sponsors and physicians from practices of all sizes to conduct clinical research more efficiently, including private practices, independent clinics, and large academic research sites. Most importantly Curebase’s methods are primarily driven by patient centricity to expand access to clinical trials for any patient, anywhere. This mission motivated Gilead, a top-20 global pharmaceutical company, to join in the funding round.

“It is more urgent than ever for the biopharmaceutical industry to transform the design and execution of our clinical programs so that we radically change the way patients experience clinical trials. We believe that by taking a human-centered design and technology enabled approach – as Curebase does – we can co-design a process that more effectively brings treatment options to people in need,” said Matt Bryant, Head of Technology and Innovation at Gilead Sciences. “Curebase’s approach will help to improve the quality, speed and patient diversity of clinical trials so that we have a more representative population in our clinical research.”

The Curebase model has been proven superior to traditional clinical trial methods. Curebase uses technology and services developed in-house to administer and manage studies across a variety of settings, including at home, in community clinics, and even in large academic centers. This has led to far faster enrollment, greater diversity among participants (32% more diverse populations on average across studies), cost savings, and a high level of patient satisfaction (97% satisfaction in a recent pivotal study receiving FDA clearance). The company has now run over 50 studies to date, with 300-400% growth year over year.

“We are pleased that investors are recognizing that Curebase is more than a software platform,” said company founder and CEO Tom Lemberg. “We are an end-to-end clinical trial company with global capabilities and an extensive site network of virtual and hybrid site staff that provides everything needed to successfully execute a better clinical trial.”

 

About Curebase

At Curebase, our mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians everywhere to enroll patients in the communities where they live. By applying cutting edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up.

Media Contact:

Shawn Malloy

media@curebase.com

315-882-5310

Curebase Secures $40M Series B

SAN FRANCISCO, May 5, 2022 — Curebase, a company committed to democratizing access to clinical studies, has raised $40 million in Series B funding to continue development of its end-to-end clinical trial execution model, virtual and hybrid site capabilities, and full eClinical software platform to run modern, patient-centric clinical trials. Since 2018,Curebase has established itself as a leader in decentralized clinical trials(DCTs) and patient-centric clinical trial software. This funding will deepen Curebase’s breadth of capabilities beyond the virtual experience: via more complex site and community healthcare interfaces, a richer range of clinical software and services, and more robust capabilities for interventional drug sponsors and global studies.

Industry Ventures led this funding round, which included new institutional investors Acrew Capital, World Innovation Lab and Positive Sum, and existing investors GGV Capital, who led the Series A, Bold Capital and Xfund. The round also included a strategic investment by global biopharmaceutical company Gilead Sciences to deepen their partnership with Curebase on implementing DCT and hybrid capabilities in interventional trials.

In addition, Gaingels, an investment syndicate that focuses on startups dedicated to building diverse and inclusive teams participated in the round. Since its founding in 2017, Curebase has raised a total of $59 million.

“We look to invest in technology companies that we believe are transforming massive, inefficient industries,” said Fanni Fan, vice president at Industry Ventures. “Curebase stood out to us for its full-vertical approach, comprehensive patient-centric software platform, and outstanding response from customers. We believe this investment will allow them to scale their model in a market that is rapidly growing on a global level, and continue expanding into the most complex drug study designs.”

Clinical research has traditionally suffered from difficult enrollment, retention, and diversity. Curebase’s model enables the inclusion of underrepresented patient populations otherwise excluded from clinical trials and expands access overall to studies to solve this challenge.  The company's virtual and hybrid research sites offer patients a unique opportunity to participate in clinical studies, regardless of their location via community provider facilities and home-based care. The Curebase platform empowers sponsors and physicians from practices of all sizes to conduct clinical research more efficiently, including private practices, independent clinics, and large academic research sites. Most importantly Curebase’s methods are primarily driven by patient centricity to expand access to clinical trials for any patient, anywhere. This mission motivated Gilead, a top-20 global pharmaceutical company, to join in the funding round.

“It is more urgent than ever for the biopharmaceutical industry to transform the design and execution of our clinical programs so that we radically change the way patients experience clinical trials. We believe that by taking a human-centered design and technology enabled approach – as Curebase does – we can co-design a process that more effectively brings treatment options to people in need,” said Matt Bryant, Head of Technology and Innovation at Gilead Sciences. “Curebase’s approach will help to improve the quality, speed and patient diversity of clinical trials so that we have a more representative population in our clinical research.”

The Curebase model has been proven superior to traditional clinical trial methods. Curebase uses technology and services developed in-house to administer and manage studies across a variety of settings, including at home, in community clinics, and even in large academic centers. This has led to far faster enrollment, greater diversity among participants (32% more diverse populations on average across studies), cost savings, and a high level of patient satisfaction (97% satisfaction in a recent pivotal study receiving FDA clearance). The company has now run over 50 studies to date, with 300-400% growth year over year.

“We are pleased that investors are recognizing that Curebase is more than a software platform,” said company founder and CEO Tom Lemberg. “We are an end-to-end clinical trial company with global capabilities and an extensive site network of virtual and hybrid site staff that provides everything needed to successfully execute a better clinical trial.”

 

About Curebase

At Curebase, our mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians everywhere to enroll patients in the communities where they live. By applying cutting edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up.

Media Contact:

Shawn Malloy

media@curebase.com

315-882-5310

Press Releases

See more

Press Releases

See More

Article Title

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing.

Entire article

Article Title

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing.

Entire article

Curebase partners with Meru Health for 3-year mental health trial

Curebase signed a three-year clinical trial with Meru Health

Entire article

Curebase and Meru Health to Partner on Clinical Research for App-based Mental Health Treatment Program

Curebase and Meru Health announce partnership on three-year clinical trial.

Entire article

Curebase Names Digital Infrastructure Veteran Matt Lanier as VP of Engineering

Curebase welcomes Matt Lanier as VP of Engineering

Entire article

Y Combinator Top Private Companies - 2022

Y Combinator released its list of top companies for 2022, this year Curebase was featured in the list of Top Private Companies.

Entire article

Curebase Names Medical Research Veteran Sean Lynch as VP of Clinical Operations

Curebase welcomes Sean Lynch as Vp of Clinical Operations

Entire article

Curebase Hires Healthcare Attorney Laura Podolsky to Head Legal Team

One of the first attorneys to specialize in DCTs, Laura Podolsky, joins Curebase as General Counsel.

Entire article

Curebase Hires Alan Sun as Vice President of Product

Alan Sun brings his passion for finding solutions that improve patient outcomes as Curebase's new VP of Product

Entire article

Curebase Releases enhanced Patient App add-on option to all studies to universally better patient participation and choice

User-friendly clinical trial solution design to increase participant engagement

Entire article

Curebase Hires HR Veteran Andi Seymour as VP of People

Andi Seymour brings over 15 years of progressive and hands-on experience to Curebase as the newly appointed VP of People.

Entire article

Curebase, Portamedic Partner to Support Decentralized Clinical Trials with Mobile Phlebotomy Services

Curebase and Portamedic partner to collect patient samples and other tests from participating DCT trial patients' homes throughout the U.S

Entire article

Curebase Hires Healthcare Technology Veteran Scott Garcia as Vice President of Finance

Scott Garcia brings 15+ years of experience scaling high-growth companies to Curebase as the new VP of Finance

Entire article

Curebase, Flow Neuroscience Announce Joint Clinical Trial  for the use of an at-home tDCS device for treating depression

Curebase and Flow Neuroscience investigate a digital therapeutic for reducing depressive symptoms.

Entire article

Curebase Adds Pharma, Clinical Research Veteran to Advisory Board

Lars-Olof "Lollo" Erkisson, Head of Clinical Development at Infant Therapeutics AB, brings cross-continental clinical operations expertise to Curebase Advisory Board

Entire article

Curebase Named Honorable Mention in Best World Changing Idea NA Category of Fast Company’s 2022 World Changing Ideas Awards

Curebase recognized by Fast Company's 2022 World Changing Ideas Awards for decentralized, patient-centric trial model

Entire article

Note to File Podcast - Episode 45: Jane Myles, Decentralized Clinical Trials: Evidence of Impact

Part 2 of Note to File Podcast with Brad Hightower featuring Jane Myles, VP of Clinical Trial Innovation at Curebase

Entire article

Curebase Selected to Launch a Clinical Investigation of a Digital Therapeutic for IPF

Curebase and Vicore Pharma partner on IPF mental health digital therapeutic study

Entire article

DCTs’ Broader and Multifaceted Implications

Curebase featured as decentralized clinical provider optimizing digital processes for patient safety and scientific advancement

Entire article

Decentralized Clinical Trials Help Level the Playing Field for Health Equity

Jane Myles, VP of Innovation at Curebase, discusses how DCTs play a role in improving health equity

Entire article

Note to File Podcast - Episode 41: Jane Myles, VP Innovation at Curebase

Jane Myles appears on Note to File Podcast with Bradley Hightower to discuss all things DCT

Entire article

Curebase Rapidly Reaches Growth Milestone

Curebase hires its 100th teammate within six months of raising Series A financing

Entire article

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health

Curebase and Blue Note Therapeutics partner on a fully virtual study comparing effectiveness of two PDTs on mental and physical health of cancer patients recently/currently undergoing treatment

Entire article

Curebase and CoBTek (team from Côte d'Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy

Curebase launching DCT study in Italy and France with a lab from the University of Côte d'Azur to improve the quality of life for elderly people

Entire article

Curebase Adds Two Clinical Trial Veterans to Kick-off New Advisory Board

Curebase welcomes Dr. Amir Lahav, leading digital health innovator, and Dr. Aaron Kamauu, leading real-world data expert, to new Advisory Board

Entire article

Curebase Joins the SCRS Global Impact Partner Program

Curebase will work closely with Society for Clinical Research Sites to advance trial site engagement and sustainability

Entire article

The Growing Case for Digital Therapeutics

Continuous developments in digital health innovations has led to the expansions of the Digital therapeutics dtx clinical trial space

Entire article

2022 Predictions for Health Equity

Healthcare IT Today features predictions from Tom Lemberg, founder and CEO of Curebase, on diversity in clinical research

Entire article

Creating New Decentralized Clinical Trial Ecosystem Including Bring Your Own Physician Option with Tom Lemberg Curebase

Tom Lemberg, founder and CEO of Curebase, talks all things BYOP (Bring Your Own Physician) on Empowered Patient Podcast

Entire article

The Future of Clinical Trials is Here Today

Curebase founder and CEO, Tom Lemberg, discusses the future of patient-centric decentralized clinical trials, including the Bring Your Own Physician (BYOP) model

Entire article

Curebase and Persephone Biosciences Partner in Clinical Trial of Colorectal Cancer Among Diverse Populations

Curebase and Persephone, collaborating with Janssen Research & Development, announce study to develop prevention strategies and treatment options for colorectal cancer (CRC) focusing on patient diversity

Entire article

Built In Honors Curebase in Its Esteemed 2022 Best Places to Work Awards

Curebase Earns Top 100 on Built In's Best Remote-First Companies to Work for in 2022

Entire article

Curebase Joins WCG Avoca Quality Consortium

Decentralized clinical trial company brings expertise in remote studies to large industry group devoted to improving trial quality

Entire article

Curebase Technology Key to metaMe Health's FDA Clearance of Regulora

Curebase serves as technology and decentralized trial execution partner for MetaMe Health's digital therapeutic dtx

Entire article

Curebase Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

Curebase recognized for achievements in Clinical Trials Tech

Entire article

Curebase CEO, Tom Lemberg, Featured in Drug Discovery and Development's "9 Predictions for Pharma in 2022"

Curebase CEO offers expert insight into the dawn of dynamic clinical trial designs

Entire article

Forbes 30 Under 30 Names Curebase CEO Tom Lemberg to it's 2022 List

Founder and CEO of Curebase receives Forbes 30 Under 30 prestigious honor for leading positive, global change in healthcare

Entire article

Curebase's Enhanced Telemedicine Feature Expands Patient Access to Edesa Biotech Derm Study

Edesa Biotech uses Curebase's eClinical platform for enhanced telemedicine that allows providers to view, measure, and record patient symptoms via the built-in application

Entire article

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Decentralized clinical trials leverages Curebase eclinical software platform, Veterans' advocacy groups

Entire article

Curebase, Checkable Medical Announce Joint Clinical Trial to Assess Effectiveness of At-home Strep Test Kit

Curebase and Checkable Medical launch first-ever at-home strep test decentralized clinical trial

Entire article

Curebase, Digital Therapeutics Alliance Announce Partnership to Accelerate Adoption of DTx Products

Curebase and DTA partner to develop a joint white paper to provide clinical trial regulatory guidance and best practices for DTx clinical evidence generation

Entire article

Curebase Solutions Supports Another InBios FDA Emergency Use Authorization for COVID-19 IgG Antibody Rapid Test

Curebase's decentralized clinical trial approach helps secure FDA Emergency Use Authorization for InBios' new COVID-19 IgG Antibody Rapid Test

Entire article

Curebase Hires Katri Langel as Senior Director of Program Development for Europe

Katri Langel, international IT and clinical research expert, joins Curebase as Senior Director of Program Development for Europe

Entire article

Curebase Hires Wayne Bowden as Vice President of Business Development

Curebase names clinical trials veteran, Wayne Bowden, as Vice President of Business Development to lead new growth and expansion efforts

Entire article

Remote Care Powered CURE-19 Platform Enables At Home COVID-19 Clinical Trials

Curebase launches the CURE-19 Platform to provide a resource for researchers seeking to better understand COVID-19 as the pandemic begins

Entire article

It's a virtual world: Curebase, AppliedVR team up on virtual reality-based, at-home clinical trials

AppliedVR will test its virtual-reality-based digital therapeutics dtx across five studies using the decentralized clinical trials software from Curebase

Entire article

Curebase Secures Jane Myles as Vice President of Clinical Trial Innovation

Curebase has named tenured clinical research expert Jane Myles as vice president of clinical trial innovation

Entire article

Introducing ‘BYOP’ Clinical Trials

Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

Curebase is participating as a CRO partner with Cofactor Genomics in first multicenter clinical trial of its OncoPrism immunotherapy response prediction assay

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

Curebase featured in Wall Street Journal among startups realizing venture capital boom in digital health

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

CLM Tests Drug Plus Digital Combo for High Blood Pressure

CLM drug and DTx digital therapeutics study with Curebase

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Curebase decentralized trials platform used to study efficacy of diagnostic test

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran, Paul Donnelly, brings more than two decades of success building healthcare companies to Curebase

Entire article

Curebase Nabs $15M for Siteless Trials that Revolve 'Around the Patient's Lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

Curebase decentralized clinical trial model will be used to study effectiveness in infections disease study

Entire article

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran brings more than two decades of success building healthcare companies

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

The success of Doximity, which went public in June and now has a market capitalization around $8.87 billion, and other digital-health startups have encouraged venture investment.

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Entire article

Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NEW YORK – Cofactor Genomics said Tuesday that it has commenced the first multicenter clinical trial of its Onco Prism immunotherapy response prediction assay, an RNA-based test developed using the company's proprietary immune modeling technology.

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

CLM tests drug plus digital combo for high blood pressure

UK biotech Closed Loop Medicine (CLM) has started recruiting patients into a trial that will test whether a drug linked to a smartphone app can improve treatment for hypertension.

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

Curebase partners with Meru Health for 3-year mental health trial

Curebase signed a three-year clinical trial with Meru Health

Entire article

Curebase and Meru Health to Partner on Clinical Research for App-based Mental Health Treatment Program

Curebase and Meru Health announce partnership on three-year clinical trial.

Entire article

Curebase Names Digital Infrastructure Veteran Matt Lanier as VP of Engineering

Curebase welcomes Matt Lanier as VP of Engineering

Entire article

Y Combinator Top Private Companies - 2022

Y Combinator released its list of top companies for 2022, this year Curebase was featured in the list of Top Private Companies.

Entire article

Curebase Names Medical Research Veteran Sean Lynch as VP of Clinical Operations

Curebase welcomes Sean Lynch as Vp of Clinical Operations

Entire article

Curebase Hires Healthcare Attorney Laura Podolsky to Head Legal Team

One of the first attorneys to specialize in DCTs, Laura Podolsky, joins Curebase as General Counsel.

Entire article

Curebase Hires Alan Sun as Vice President of Product

Alan Sun brings his passion for finding solutions that improve patient outcomes as Curebase's new VP of Product

Entire article

Curebase Releases enhanced Patient App add-on option to all studies to universally better patient participation and choice

User-friendly clinical trial solution design to increase participant engagement

Entire article

Curebase Hires HR Veteran Andi Seymour as VP of People

Andi Seymour brings over 15 years of progressive and hands-on experience to Curebase as the newly appointed VP of People.

Entire article

Curebase, Portamedic Partner to Support Decentralized Clinical Trials with Mobile Phlebotomy Services

Curebase and Portamedic partner to collect patient samples and other tests from participating DCT trial patients' homes throughout the U.S

Entire article

Curebase Hires Healthcare Technology Veteran Scott Garcia as Vice President of Finance

Scott Garcia brings 15+ years of experience scaling high-growth companies to Curebase as the new VP of Finance

Entire article

Curebase, Flow Neuroscience Announce Joint Clinical Trial  for the use of an at-home tDCS device for treating depression

Curebase and Flow Neuroscience investigate a digital therapeutic for reducing depressive symptoms.

Entire article

Curebase Adds Pharma, Clinical Research Veteran to Advisory Board

Lars-Olof "Lollo" Erkisson, Head of Clinical Development at Infant Therapeutics AB, brings cross-continental clinical operations expertise to Curebase Advisory Board

Entire article

Curebase Named Honorable Mention in Best World Changing Idea NA Category of Fast Company’s 2022 World Changing Ideas Awards

Curebase recognized by Fast Company's 2022 World Changing Ideas Awards for decentralized, patient-centric trial model

Entire article

Note to File Podcast - Episode 45: Jane Myles, Decentralized Clinical Trials: Evidence of Impact

Part 2 of Note to File Podcast with Brad Hightower featuring Jane Myles, VP of Clinical Trial Innovation at Curebase

Entire article

Curebase Selected to Launch a Clinical Investigation of a Digital Therapeutic for IPF

Curebase and Vicore Pharma partner on IPF mental health digital therapeutic study

Entire article

DCTs’ Broader and Multifaceted Implications

Curebase featured as decentralized clinical provider optimizing digital processes for patient safety and scientific advancement

Entire article

Decentralized Clinical Trials Help Level the Playing Field for Health Equity

Jane Myles, VP of Innovation at Curebase, discusses how DCTs play a role in improving health equity

Entire article

Note to File Podcast - Episode 41: Jane Myles, VP Innovation at Curebase

Jane Myles appears on Note to File Podcast with Bradley Hightower to discuss all things DCT

Entire article

Curebase Rapidly Reaches Growth Milestone

Curebase hires its 100th teammate within six months of raising Series A financing

Entire article

Curebase and Blue Note Therapeutics Collaborate on Home-based Clinical Trial of Prescription Digital Therapeutics to Help People with Cancer Manage their Health

Curebase and Blue Note Therapeutics partner on a fully virtual study comparing effectiveness of two PDTs on mental and physical health of cancer patients recently/currently undergoing treatment

Entire article

Curebase and CoBTek (team from Côte d'Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy

Curebase launching DCT study in Italy and France with a lab from the University of Côte d'Azur to improve the quality of life for elderly people

Entire article

Curebase Adds Two Clinical Trial Veterans to Kick-off New Advisory Board

Curebase welcomes Dr. Amir Lahav, leading digital health innovator, and Dr. Aaron Kamauu, leading real-world data expert, to new Advisory Board

Entire article

Curebase Joins the SCRS Global Impact Partner Program

Curebase will work closely with Society for Clinical Research Sites to advance trial site engagement and sustainability

Entire article

The Growing Case for Digital Therapeutics

Continuous developments in digital health innovations has led to the expansions of the Digital therapeutics dtx clinical trial space

Entire article

Creating New Decentralized Clinical Trial Ecosystem Including Bring Your Own Physician Option with Tom Lemberg Curebase

Tom Lemberg, founder and CEO of Curebase, talks all things BYOP (Bring Your Own Physician) on Empowered Patient Podcast

Entire article

2022 Predictions for Health Equity

Healthcare IT Today features predictions from Tom Lemberg, founder and CEO of Curebase, on diversity in clinical research

Entire article

The Future of Clinical Trials is Here Today

Curebase founder and CEO, Tom Lemberg, discusses the future of patient-centric decentralized clinical trials, including the Bring Your Own Physician (BYOP) model

Entire article

Curebase and Persephone Biosciences Partner in Clinical Trial of Colorectal Cancer Among Diverse Populations

Curebase and Persephone, collaborating with Janssen Research & Development, announce study to develop prevention strategies and treatment options for colorectal cancer (CRC) focusing on patient diversity

Entire article

Built In Honors Curebase in Its Esteemed 2022 Best Places to Work Awards

Curebase Earns Top 100 on Built In's Best Remote-First Companies to Work for in 2022

Entire article

Curebase Joins WCG Avoca Quality Consortium

Decentralized clinical trial company brings expertise in remote studies to large industry group devoted to improving trial quality

Entire article

Curebase Technology Key to metaMe Health's FDA Clearance of Regulora

Curebase serves as technology and decentralized trial execution partner for MetaMe Health's digital therapeutic dtx

Entire article

Curebase Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

Curebase recognized for achievements in Clinical Trials Tech

Entire article

Curebase CEO, Tom Lemberg, Featured in Drug Discovery and Development's "9 Predictions for Pharma in 2022"

Curebase CEO offers expert insight into the dawn of dynamic clinical trial designs

Entire article

Forbes 30 Under 30 Names Curebase CEO Tom Lemberg to it's 2022 List

Founder and CEO of Curebase receives Forbes 30 Under 30 prestigious honor for leading positive, global change in healthcare

Entire article

Curebase's Enhanced Telemedicine Feature Expands Patient Access to Edesa Biotech Derm Study

Edesa Biotech uses Curebase's eClinical platform for enhanced telemedicine that allows providers to view, measure, and record patient symptoms via the built-in application

Entire article

Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better

Decentralized clinical trials leverages Curebase eclinical software platform, Veterans' advocacy groups

Entire article

Curebase, Checkable Medical Announce Joint Clinical Trial to Assess Effectiveness of At-home Strep Test Kit

Curebase and Checkable Medical launch first-ever at-home strep test decentralized clinical trial

Entire article

Curebase, Digital Therapeutics Alliance Announce Partnership to Accelerate Adoption of DTx Products

Curebase and DTA partner to develop a joint white paper to provide clinical trial regulatory guidance and best practices for DTx clinical evidence generation

Entire article

Curebase Solutions Supports Another InBios FDA Emergency Use Authorization for COVID-19 IgG Antibody Rapid Test

Curebase's decentralized clinical trial approach helps secure FDA Emergency Use Authorization for InBios' new COVID-19 IgG Antibody Rapid Test

Entire article

Curebase Hires Katri Langel as Senior Director of Program Development for Europe

Katri Langel, international IT and clinical research expert, joins Curebase as Senior Director of Program Development for Europe

Entire article

Curebase Hires Wayne Bowden as Vice President of Business Development

Curebase names clinical trials veteran, Wayne Bowden, as Vice President of Business Development to lead new growth and expansion efforts

Entire article

It's a virtual world: Curebase, AppliedVR team up on virtual reality-based, at-home clinical trials

AppliedVR will test its virtual-reality-based digital therapeutics dtx across five studies using the decentralized clinical trials software from Curebase

Entire article

Curebase Secures Jane Myles as Vice President of Clinical Trial Innovation

Curebase has named tenured clinical research expert Jane Myles as vice president of clinical trial innovation

Entire article

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

Curebase decentralized clinical trial model will be used to study effectiveness in infections disease study

Entire article

Introducing ‘BYOP’ Clinical Trials

Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran, Paul Donnelly, brings more than two decades of success building healthcare companies to Curebase

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

Curebase featured in Wall Street Journal among startups realizing venture capital boom in digital health

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Curebase decentralized trials platform used to study efficacy of diagnostic test

Entire article

Curebase Nabs $15M for Siteless Trials that Revolve 'Around the Patient's Lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

Curebase is participating as a CRO partner with Cofactor Genomics in first multicenter clinical trial of its OncoPrism immunotherapy response prediction assay

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

CLM Tests Drug Plus Digital Combo for High Blood Pressure

CLM drug and DTx digital therapeutics study with Curebase

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

Remote Care Powered CURE-19 Platform Enables At Home COVID-19 Clinical Trials

Curebase launches the CURE-19 Platform to provide a resource for researchers seeking to better understand COVID-19 as the pandemic begins

Entire article

Subscribe to Curebase Content

Interested in staying up to date with Curebase's latest developments in the decentralized clinical trial space? Get regular updates on news, webinars, blogs and more by subscribing here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States